News Releases

Date	Title and Summary	View
July 1, 2020	KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results – KVD900 Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) Data Expected in 2H 2020 – – Oral HAE Prophylactic Candidate KVD824 Phase 2 Clinical Trial Planned to Commence in 2H 2020 – – Operations Funded into 2022 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul....	Additional Formats PDF Version
May 28, 2020	KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...	Additional Formats PDF Version
April 9, 2020	KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 9, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...	Additional Formats PDF Version
April 7, 2020	KalVista Pharmaceuticals Provides Operational and Financial Update – Response to Coronavirus Impact on Ongoing Clinical Trials – – Cash Runway Extended into 2022 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 7, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and...	Additional Formats PDF Version
March 10, 2020	KalVista Pharmaceuticals Reports Fiscal Third Quarter Results – Oral Hereditary Angioedema Franchise Phase 2 Clinical Trials on Track – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule...	Additional Formats PDF Version
February 19, 2020	KalVista Pharmaceuticals to Present at SVB Leerink 9th Annual Global Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 19, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...	Additional Formats PDF Version
February 10, 2020	KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs – Merck Option Agreement Expires – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 10, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,...	Additional Formats PDF Version
January 13, 2020	KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise – KVD900 Phase 2 Clinical Trial Data Anticipated in Q2 2020 – – KVD824 Selected for Prophylactic Treatment; Phase 2 Expected to Initiate in H2 2020 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 13, 2020-- KalVista Pharmaceuticals, Inc....	Additional Formats PDF Version